A5063230228- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Renal and related cancers
- Multiple and Secondary Primary Cancers
- Nutrition and Health in Aging
- Inflammatory Biomarkers in Disease Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Chronic Kidney Disease and Diabetes
- Urological Disorders and Treatments
- Pediatric Urology and Nephrology Studies
- MRI in cancer diagnosis
- Renal and Vascular Pathologies
- Frailty in Older Adults
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Genital Health and Disease
- Reproductive Health and Technologies
- Urinary Bladder and Prostate Research
- Male Reproductive Health Studies
Emory University
2016-2025
AstraZeneca (Brazil)
2024
Bayer (United States)
2024
Eisai (Japan)
2024
AstraZeneca (Canada)
2024
Incyte (United States)
2024
Exelixis (United States)
2024
Bristol-Myers Squibb (Germany)
2024
Merck (Singapore)
2024
Roche (Switzerland)
2024
Importance Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection indolent cancers resulting from the poor specificity PSA for high-grade PCa (ie, grade group [GG] 2 or greater). Objective To develop a multiplex urinary panel validate its external performance relative to current guideline-endorsed biomarkers. Design, Setting, Participants RNA sequencing analysis 58 724 genes identified 54 markers...
We evaluated the ability of PHI to discriminate aggressive prostate cancer from indolent or no in a biopsy naïve population.
Patients with metastatic renal cell cancer (mRCC) who respond to upfront immune checkpoint inhibitor (ICI) combination therapies may be treated cytoreductive nephrectomy (CN) remove radiographically viable primary tumors. Early data for post-ICI CN suggested that ICI induce desmoplastic reactions in some patients, increasing the risk of surgical complications and perioperative mortality. We evaluated outcomes 75 consecutive patients at four institutions from 2017 2022. Our cohort had minimal...
No AccessJournal of UrologyAdult Urology1 Aug 2017Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus E. Jason Abel, Philippe Spiess, Vitaly Margulis, Viraj A. Master, Michael Mann, Kamran Zargar-Shoshtari, Leonardo D. Borregales, Wade J. Sexton, Datta Patil, Surena F. Matin, Christopher G. Wood, and Jose Karam AbelE. Abel Department Urology, University Wisconsin School Medicine Public Health, Madison, More articles by this author , SpiessPhilippe Spiess...
Background MicroRNAs (miRNAs) have been linked to prostate cancer (PC) risk; however, their role as a screening biomarker for PC has yet be determined. We examined whether circulating miRNAs in plasma could potential biomarkers the early detection of among men undergoing needle biopsy. Methods Men who had biopsy due an abnormal test were recruited. Linear regression was used examine association between and status model individual miRNA expression on serum PSA age calculate partial...
Liquid biopsies that noninvasively detect molecular correlates of aggressive prostate cancer (PCa) could be used to triage patients, reducing the burdens unnecessary invasive biopsy and enabling early detection high-risk disease. DNA hypermethylation is among earliest most frequent aberrations in PCa. We investigated accuracy a six-gene methylation panel (Epigenetic Cancer Prostate Test Urine [epiCaPture]) at detecting PCa, high-grade (Gleason score greater than or equal 8) (D'Amico Risk...
Body composition and inflammation are gaining importance for prognostication in cancer. This study investigated the individual combined utility of preoperative skeletal muscle index (SMI) modified Glasgow Prognostic Score (mGPS) estimating postoperative outcomes patients with localized renal cell carcinoma (RCC) undergoing nephrectomy.The authors performed a retrospective review 352 RCC. SMI was measured via computed tomography or magnetic resonance imaging. Patients met criteria sarcopenia...
519 Background: Positive surgical margins (PSM) are associated with worsened survival outcomes in Renal Cell Carcinoma (RCC). Current AUA guidelines recommend intensified post-surgical follow-up and clinical vigilance patients PSM. We sought to evaluate of different RCC-histologies microscopic-PSM. Methods: performed a retrospective analysis undergoing partial nephrectomy (PN) or radical (RN) for RCC who had The cohort was divided according RCC-Histology [Chromophobe-RCC (chRCC); Clear...
515 Background: While immunotherapy has become first-line treatment for metastatic renal cell carcinoma in both clear (ccRCC) and non-clear (nccRCC) histologies, there been limited investigation into adjuvant therapies nccRCC the context of high-risk localized RCC. As Pembrolizumab is being more commonly employed non-metastatic ccRCC, its application remains less understood. This study aims to compare survival outcomes between patients with ccRCC nccRCC, focusing on cancer-specific (CSS)...
527 Background: Patients presenting with symptomatic renal cell carcinoma (RCC) tend to have more aggressive disease and poorer prognosis. Paraneoplastic syndromes (PNS), manifesting as atypical symptoms or abnormal laboratory values, are similarly associated worse outcomes. However, the impact of PNS on prognosis remains unclear. The aim this study is develop a Symptomatic Score (PNSS) better predict by considering clinical presentation presence at diagnosis. Methods: Prospectively...
370 Background: Radical prostatectomy (RP) and radiotherapy are standard-of-care treatments for localized prostate cancer. We studied the contemporary trends in utilization costs of radiotherapeutic modalities U.S. Methods: analyzed MarketScan Medicare Supplemental Coordination Benefits (MDCR) Commercial Claims Encounters (CCAE) Databases (the latter includes patients insured by employer-sponsored plans). identified men with non-metastatic cancer treated RP, external beam radiation therapy...
565 Background: β2 microglobulin is a nonglycosylated protein synthesized by all nucleated cells. It has been utilized as tumor marker in several different malignancies, however, studies examining its role renal cell carcinoma (RCC) are limited. Methods: Using the Emory kidney cancer database, patients with any stage or histology RCC who underwent partial radical nephrectomy from 2000 to 2022 and had an available within 90 days before surgery were included. ≥ 2.34 mg/L was considered...